Dataset Viewer
text
stringlengths 1
194
|
|---|
detection, elimination (PARADE): a position paper of the
|
30.3 � 10.5
|
hypertensive
|
this finding was unexpected, and further studies might be
|
the Kolmogorov–Smirnov test. To compare continuous
|
GROUP
|
patients with hypertension. J Int Med Res 2001; 29(4):270–279.
|
5–10 mg/day), for 12 weeks immediately after baseline
|
and cardiology outpatient clinics who had a newly diagnosed essential hypertension were included in the study. A
|
effect of 12 weeks of antihypertensive therapy with valsartan on lipid parameters is shown in Table 3.
|
BMI. Mean SBP and DBP were 156.05 � 9.3 and 92.3
|
associations and confirm their clinical relevance for macrovascular and microvascular morbidity and mortality.
|
role of valsartan in lipid-lowering function.
|
[29] Andrzejczak D, Gorska D, Czarnecka E. Influence of amlodipine
|
[24] Ahaneku J, Taylor G, Agbedana E, Walker O, Salako L. Changes
|
variables, independent samples t test or Mann–Whitney
|
and diuretics (7) have negative effects on lipid metabolism, whereas calcium channel blockers, particularly
|
93.8 � 8.7
|
2012. doi:10.3109/10641963.2012.681722. [Epub ahead of print].
|
cardiovascular disease independent of high-density lipoprotein
|
.084
|
Clinical and Experimental Hypertension, 2013; 35(6): 449–453
|
prevention of cardiovascular disease (4,5).
|
[7] Neutel J. Metabolic manifestations of low-dose diuretics. Am J
|
Although the mechanisms behind the drug-caused dyslipidemia is still uncertain, it has been said that valsartan
|
therapy on serum lipids. Ann Intern Med 1995; 122(2):133–141.
|
effects of valsartan with placebo in patients with mild to
|
levels and apolipoprotein A and B levels significantly in
|
88.3 � 4.8
|
the
|
5.0 � 0.94
|
Males/females
|
angiotensin II receptor blocker (valsartan, 80–320 mg/
|
INTRODUCTION
|
same assay. Fasting plasma glucose, total cholesterol
|
of
|
results of previous studies that examined the effects of
|
antihypertensive
|
Abbreviations: HDL – high density lipoprotein; LDL – low density
|
RESULTS
|
and LDL cholesterol levels in comparison to valsartan.
|
[12] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
|
As a result, in the treatment of hypertension, prior
|
(Prinzmetal’s angina and chronic stable angina pectoris),
|
chair for 10 minutes, and then the systolic blood pressure
|
Dis
|
[28] Delsing DJM, Jukema JW, Wiel MAVD, Princen HMG.
|
For personal use only.
|
P
|
on
|
patients
|
affect lipid metabolism but others are observed to have
|
elevated lipids and hypertension (AVALON) trial, coadministration of amlodipine (5 mg) and atorvastatin
|
these drugs are metabolically neutral and cause few lipoprotein alterations (24). In a previous study, significant
|
after treatment were 157.2 � 10.0 and 127.0 �
|
Hypertension 2006; 47(1):45–50.
|
.914
|
(SBP) and diastolic blood pressure (DBP) were recorded
|
BMI (kg/m2)
|
In the amlodipine group, there was a significant
|
be taken into consideration while prescribing antihypertensive drugs in patients with clear evidence of dyslipidemia.
|
154.2 � 57.2
|
said that it might potentiate the antiatherosclerotic effect
|
450
|
Pharmacol 1998; 31(4):576–580.
|
Table 1. Demographics, anthropometrics, baseline characteristics,
|
In an animal study, it was demonstrated that amlodipine treatment alone did not significantly reduce atherosclerotic lesion development, and in cotreatment, it was
|
.804
|
(LPS)-induced
|
For personal use only.
|
affect bradykinin or prostaglandin metabolism like
|
BP that is described as newly diagnosed essential hypertension aiming at the smaller time from the start point.
|
[16] Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59(11):3140–3148.
|
Rajagopalan et al., the effects of valsartan and valsartanstatin combination were compared in hypertensive patients,
|
100.0
|
Diastolic BP (mm Hg)
|
for its positive or negative effects on the lipid profile.
|
1:6–11.
|
metabolic abnormalities—the role of insulin resistance and the
|
BP – blood pressure; MCV – mean corpuscular volume, MPV mean platelet volume, WBC – white blood cell, HDL – high density
|
Hypertensive patients, which constitute a group at high
|
207.4 � 33.1
|
Clin Exp Hypertens Downloaded from informahealthcare.com by Nyu Medical Center on 10/16/14
|
Currently, even for patients on antihyperlipidemic drug
|
[3] Hokanson J, Austin M. Plasma triglyceride level is a risk factor for
|
of amlodipine was coadministered with 10 mg of atorvastatin, the LDL level was reduced than that with 10 mg of
|
Systolic BP (mm Hg)
|
on serum lipids, or at least it may show no imrovement,
|
coefficient evaluated the degree of linear association
|
Creatinine (mg/dL)
|
were separated, and all plasma samples were run in the
|
patients. The aim of the present study was to investigate
|
measured before treatment and in the 12th week. None
|
(amlodipine,
|
the angiotensin II-receptor antagonist losartan in Japanese
|
characterized by high TG levels (14,15). Our study
|
on the lipid profile in patients with essential hypertension.
|
MCV (fL)
|
study by Preston et al., it was expressed that when 5 mg
|
.005
|
End of preview. Expand
in Data Studio
- Downloads last month
- 5